Acute myocardial infarction in young women: current perspectives

This article was published in the following Dove Press journal:
International Journal of Women's Health

Jaya Chandrasekhar¹
Amrita Gill¹,²
Roxana Mehran¹
¹Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY, ²Saint Louis University, St Louis, MO, USA

Abstract: Acute myocardial infarction (AMI) is the leading cause of death in women worldwide. Every year, in the USA alone, more than 30,000 young women <55 years of age are hospitalized with AMI. In recent decades, the incidence of AMI is increasing in younger women in the context of increasing metabolic syndrome, diabetes mellitus, and non-traditional risk factors such as stress, anxiety, and depression. Although women are classically considered to present with atypical chest pain, several observational data confirm that men and women experience similar rates of chest pain, with some differences in intensity, duration, radiation, and the choice of descriptors. Women also experience more number of symptoms and more prodromal symptoms compared with men. Suboptimal awareness, sociocultural and financial reasons result in pre-hospital delays in women and lower rates of access to care with resulting undertreatment with guideline-directed therapies. Causes of AMI in young women include plaque-related MI, microvascular dysfunction or vasospasm, and spontaneous coronary artery dissection. Compared with men, women have greater in-hospital, early and late mortality, as a result of baseline comorbidities. Post-AMI women have lower referral to cardiac rehabilitation with more dropouts, lower levels of physical activity, and poorer improvements in health status compared with men, with higher inflammatory levels at 1-year from index presentation. Future strategies should focus on primary and secondary prevention, adherence, and post-AMI health-related quality of life. This review discusses the current evidence in the epidemiology, diagnosis, and treatment of AMI in young women.

Keywords: acute myocardial infarction, young women, sex differences, women's health

Introduction

Acute myocardial infarction (AMI) has historically been regarded as a man’s disease, and for many years, women have been underdiagnosed and undertreated. Bernadine Healy, the erstwhile director of the US National Institutes of Health, classically referred to this as the Yentl syndrome, describing women who were not recognized as experiencing AMI unless they presented with male-pattern chest pain symptoms.¹,² Since that time, significant efforts from different stakeholder groups have culminated in greater awareness and improved measures to recognize and manage AMI and coronary artery disease (CAD) in women. Yet, as a consequence of contemporary lifestyles and increasing prevalence of obesity, the incidence of AMI continues to increase, particularly in young women, who comprise a special high-risk population. It is crucial for both physicians and young individuals to be aware of disease risk factors, as well as cardiovascular signs and symptoms, in order to mitigate symptom to presentation times, toward optimizing patient care. In the current review, we discuss temporal trends in the incidence of AMI, evolving risk factors, pathophysiology, and evidence from recent clinical studies with a focus on young women. Figure 1 illustrates
the comprehensive issues surrounding management of AMI in young women.

A few important studies specifically designed to examine female-specific risk factors and outcomes in ischemic heart disease (IHD) or AMI are worthy of mention.3–5 These studies examined the role of female sex, gender, and non-traditional risk factors for AMI and CAD. The National Heart Lung and Blood Institute sponsored multicenter Women’s Ischemia Evaluation (WISE) Study investigated the mechanisms of non-obstructive disease in women and the influence of reproductive hormones on the evaluation of IHD in women.3,6 The Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients (VIRGO) study was a multicenter international observational study that compared young women between 30 and 55 years of age to young men enrolled at the time of AMI presentation (Table 1).4 The GEnDer and Sex determinantS of cardiovascular disease: from bench to beyond-Premature Acute Coronary SYndrome (GENESIS PRAXY) multicenter study was designed to examine outcomes in men and women between 18 and 55 years of age with premature acute coronary syndrome (ACS) in which gender-related characteristics were measured using a self-administered questionnaire (Table 2).5,7

Incidence of AMI

The American Heart Association (AHA) Scientific Statement describes cardiovascular death as an equal opportunity killer, and while decline in AMI deaths has been noted in both men and women since the year 2000, rates are decreasing more so in men than in women.8 Talbott et al studied US Centers of Disease Control National Environmental Public Health Tracking Network data from 20 US participating states and showed that between 2000 and 2008, AMI rates decreased by 20% in men and in women.9 However, using data from the US National Inpatient Sample (NIS) from 1997 to 2006, Towfighi et al noted that MI hospitalization rates decreased over time by 26% in men but only 18% in women between the ages of 35 and 64 years.10 In fact, MI hospitalization rates increased for women 35–44 years and decreased only slightly for women 45–54 years and men 35–44 years. Recently, Izadnegahdar et al studied 70,628 AMI hospitalizations (17.1% ≤55 years of age) between 2000 and 2009 in British Columbia, Canada.11 Age-standardized AMI rates declined in men and women in similar manner; however, interaction was noted by age-sex-year with increasing rates noted only in younger women (+1.7%/year). Younger women also continued to have higher mortality rates than younger men.

Recent data from the Agency for Healthcare Research and Quality’s (AHRQ) Healthcare Cost and Utilization Project (HCUP)-NIS for the period 2001–2010 showed that in 230,684 patients between 30 and 54 years of age, overall, there was no increase in the incidence of AMI presentations in either sex over time.12 However, while women showed no change or increase in hospitalization

Figure 1 Current issues surrounding AMI management in young women.

Abbreviations: AMI, acute myocardial infarction; PCI, percutaneous coronary intervention; SCAD, spontaneous coronary artery dissection.
Generic health scores were tested with Short form-12 physical health and mental health questionnaire,

More women than men have financial barriers for medications (22.3% vs 17.2%; adjusted HR 1.23,

Twelve percent patients stopped statin by 1 month follow-up.

Women are more likely to exceed in-hospital and transfer time guidelines (41% women vs 29% men, OR 1.65).

Few patients receive sexual health counseling after AMI. Patients are often provided incorrect advice not in

There was no difference in reperfusion strategy between women and men.

Young women and men with AMI perceived similar levels of social support at baseline (low social support

Patients with financial barriers had worse mental function status, more depression, stress, and poor quality of life.

Key outcomes

Women have poorer pre-event health status: with lower generic and disease-specific health scores.

N

Women have poorer health scores than men at baseline and throughout follow-up after AMI.

More than 90% of women and men are discharged on statin after AMI.

Financial barriers are common after AMI and associated with worse 1-year outcomes.

Disease-specific health status was tested with Seattle angina scores.

Follow-up

Lu et al\textsuperscript{111}

N=2985

(2,009 women); 2,985

Less than half of young AMI patients received a high intensity statin at discharge.

1 month follow-up in N=2,219

Twelve percent patients stopped statin by 1 month follow-up.

Although LDL reduced to <100 mg/dL in both men and women, HDL remained <40 mg/dL at 1 month.

Dreyer et al\textsuperscript{98}

N=3,501

(2,349 women)

Women have poorer pre-event health status: with lower generic and disease-specific health scores.

Dreyer et al\textsuperscript{99}

N=3,501

(2,349 women)

Women have poorer health scores than men at baseline and throughout follow-up after AMI.

Dreyer et al\textsuperscript{98}

N=3,501

(2,349 women)

Women have poorer health scores than men at baseline and throughout follow-up after AMI.

Dreyer et al\textsuperscript{99}

N=3,501

(2,349 women)

Women have poorer health scores than men at baseline and throughout follow-up after AMI.

Minges et al\textsuperscript{107}

N=3,466

(2,322 women)

Men were more active than women at baseline (42% vs 34%), 1 month (43% vs 34%), and 12 months

washing (48% vs 36%) post-ACS, participating in guideline-directed exercise (moderate activity =150 minutes per

week or vigorous activity =75 minutes per week).

Men participated in longer duration of activity than women.

Lindau et al\textsuperscript{110}

N=3,501

(2,349 women)

Few patients receive sexual health counseling after AMI. Patients are often provided incorrect advice not in

keeping with the guidelines.

Beckman et al\textsuperscript{112}

N=3,437

(2,306 women)

Financial barriers are common after AMI and associated with worse 1-year outcomes.

More women than men have financial barriers for medications (22.3% vs 17.2%; adjusted HR 1.23,

95% CI =1.01–1.51).

Women and men reported financial barriers equally to services (31.3% vs 28.9%)

Patients with financial barriers had worse mental function status, more depression, stress, and poor quality of life.

Bucholz et al\textsuperscript{109}

N=3,432

(2,303 women)

Young women and men with AMI perceived similar levels of social support at baseline (low social support

perceived by 1 in 5 men and women; 21.4% women vs 20.9% men).

Low social support was associated with lower mental functioning, quality of life, and depressive symptoms at

12 months.

Abbreviations: ACS, acute coronary syndrome; AMI, acute myocardial infarction; CAD, coronary artery disease; CHF, coronary heart failure; ECG, electrocardiography; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation MI.
Table 2 Important findings from the GENdEr and Sex determinantS of cardiovascular disease: from bench to beyond-Premature Acute Coronary Syndrome study

<table>
<thead>
<tr>
<th>Author</th>
<th>Sample size</th>
<th>Key outcomes</th>
</tr>
</thead>
</table>
| Pelletier et al<sup>34</sup> | 1,123 patients | • Fewer young women than men received ECG or fibrinolysis within benchmark times.  
• Women with STEMI were less likely to undergo reperfusion.  
• Women with NSTEMI were less likely to undergo PCI.  
• Absence of chest pain, anxiety, and increased number of risk factors were determinants of poorer access to care. |
| Choi et al<sup>17</sup> | 1,015 patients | • Women had more traditional (diabetes, hypertension, dyslipidemia, smoking, and obesity) and non-traditional (anxiety, depression, and low household income) risk factors compared with men.  
• However, median 10-year Framingham risk score was lower in women (7% vs 13%) whereas 30-year Framingham risk score was 36% in women and 44% in men.  
• Consideration of non-traditional risk factors and 30-year rather than 10-year Framingham risk might more accurately classify women. |
| Pelletier et al<sup>34</sup> | 273 women, 636 men | • Female sex was not associated with increased risk of adverse outcomes.  
• However, feminine roles and traits are associated with greater risk of recurrent ACS (HR 4.5, 95% CI =1.05–19.27) and a trend for greater MACE (HR 1.54, 95% CI =0.90–2.66) than masculine characteristics. |
| Afshar et al<sup>13</sup> | 939 patients (33.1% women) | • Lipoprotein (a) is associated with high LDL levels in young patients with ACS.  
• When adjusted for increased anxiety, these associations were no longer significant.  
• Patients with high lipoprotein (a) and LDL levels $>3.5$ mmol may warrant more aggressive lipid lowering. |
| Follow-up | Leung-Yinko et al<sup>14</sup> | 740 patients | • Women and men with ACS had worse baseline health than the general population. At 1 year post-ACS, only 1% more women and 5% more men reported intake $\geq5$ daily servings of fruits and vegetables, which was lower than in the general population.  
• Women continued to smoke twice as often as men at 1 year. |
| Leung-Yinko et al<sup>15</sup> | 439 participants | • Gender-related factors such as social support but not sex influenced health-related quality of life 1 year post-ACS. |

Abbreviations: ACS, acute coronary syndrome; ECG, electrocardiography; LDL, low-density lipoprotein; MACE, major adverse cardiac events; MI, myocardial infarction; NSTEMI, non-STEMI; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation MI.

rates for AMI, men showed decreases in hospitalization rates. Women comprised only 25.9% of all patients but more women than men were Black (19.7% vs 10.5%). Black women in this analysis had higher hospitalization rates than White women, while rates were comparable for Black and White men. Further, Wang et al analyzed NIS data in the HCUP for patients between 2001 and 2007 across different age groups and also observed greater declines in MI hospitalization in White men and women (30.8% and 31.4%, respectively) compared with Black men and women (13.6% and 12.6%, respectively), regardless of age category.<sup>13</sup>

Yeh et al presented data from the California Kaiser Permanente system for MI hospitalizations between 1999 and 2008.<sup>14</sup> Interestingly, the proportion of ST-segment elevation MI (STEMI) halved over this time; however, the age- and sex-adjusted incidence of Non-STEMIs (NSTEMI) increased. This was confirmed by other observational analyses, including a recent analysis from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Get With The Guidelines database.<sup>13</sup> Similarly, Zhang et al studied 77,943 Chinese AMI patients in Beijing between 2001 and 2012; AMI rates increased over time by 31.2% from 55.8 to 73.3 per 100,000 population.<sup>16</sup> Although there was a decrease in STEMI, there was a threefold increase in the rate of NSTEMI.

**Prevalence of risk factors**

Studies have consistently shown that young women presenting with ACS have significantly greater comorbidities than young men, including smoking, diabetes, metabolic syndrome, hypertension, and chronic kidney disease.<sup>17</sup>–<sup>20</sup> In the Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) trial, 70.5% women <65 years of age compared to 56.6% men ($p=0.02$) reported history of smoking.<sup>20</sup> Additionally, nearly two-thirds of women in this age group had metabolic syndrome at baseline (62.8% women vs 45.5% men, $p=0.004$). In general, the prevalence of obesity and diabetes is increasing in US adults in both men and women.<sup>21</sup> Even though the age-adjusted prevalence of metabolic syndrome has been reported to fall in women between 1999 and 2010 (with a peak in 2001–2002), there has been an increase in the prevalence of hypertriglyceridemia and increasing waist circumference attributed to decreasing physical activity, intake of fast food and sugar-sweetened beverages, and shorter sleep duration.<sup>22</sup>
While diabetes is considered a risk equalizer for overriding the benefits of estrogen in women, non-diabetic women have similar outcomes to diabetic men; thus, female sex itself lends risk equivalence to diabetes mellitus in men. Women with AMI also have greater prevalence of other comorbidities including congestive heart failure, chronic obstructive lung disease, and poor baseline mental health, with higher inflammatory markers than men. In one study, although women presented less often with STEMI than men (50% vs 57%, \( p=0.007 \)), they had higher rates of Global Registry of Acute Coronary Events (GRACE) score \( \geq 140 \) (19% vs 12%, \( p=0.007 \)).

Young women also have greater prevalence of depression, anxiety, and stress, with higher depression and stress scores at the time of AMI presentation compared with men, as a function of greater comorbidities, familial conflict, financial concerns, and caregiving demands. Certainly, untreated depression in AMI patients is correlated with greater risk of 1-year mortality than patients with treated depression or patients without history of depression. In the GENESIS-PRAXY study, young women had greater traditional risk factors than young men, but also greater non-traditional risk factors such as anxiety, low household income, and depression (Figure 2). Use of 10-year Framingham risk score in this study did not correctly capture risk in young individuals, and the authors recommended that incorporation of non-traditional risk factors and consideration of 30-year Framingham risk score may more appropriately classify these patients. Further, from this study, female gender encompassing social and cultural factors, namely, stress level and responsibility at home, stress management, femininity score, primary earner status, number of hours worked per week, and social support, were observed to be more important than sex for health-related quality of life outcomes after ACS.

Young women with history of adverse pregnancy outcomes are at higher risk of accelerated atherosclerosis and premature CAD. While premenopausal women are thought to be of low risk from a cardiovascular perspective due to the protective effects of estrogen, the higher rates of traditional cardiovascular risk factors outweigh these benefits. In the WISE study, premenopausal women with angiographic CAD had lower levels of estradiol than women without angiographic disease, and hypothalamic hypoestrogenemia was noted to be a multivariate predictor of outcomes. Premenopausal women may also be at higher risk of MI when estrogen level is low such as during the menstrual and follicular phases of the menstrual cycle. Indeed, higher levels of follicular-phase estrogen were associated with more favorable metabolic and hemostatic factors. Nevertheless, postmenopausal hormone replacement therapy, although shown to be beneficial in the Nurses’ Health Study and the Danish Osteoporosis prevention study, has not proven to be of benefit in several randomized controlled trials.

Symptoms and signs
Some studies have reported that more women commonly present with atypical right-sided chest pain, neck or shoulder

![Figure 2 Sex differences in non-traditional risk factors among young AMI patients.](https://www.dovepress.com/)

**Figure 2** Sex differences in non-traditional risk factors among young AMI patients.

**Note:** Data taken from the GENESIS-PRAXY study, Choi et al.

**Abbreviation:** AMI, acute myocardial infarction.
pain compared with men who experience typical left-sided chest pain radiating to the left shoulder and jaw.\textsuperscript{22} In a retrospective survey study conducted in 1,270 women, 96% of women documented prodromal symptoms at the time of ACS presentation, and unusual fatigue (73%) and sleep disturbance (50%) were the most common symptoms.\textsuperscript{3} In the GENESIS-PRAXY study,\textsuperscript{38} women reported more prodromal symptoms than men (85% vs 79%, \(p<0.001\)) and a greater number of symptoms (6 vs 4, \(p<0.001\)) including fatigue, sleep disturbances, anxiety, and arm weakness or discomfort.

However, from the Advantageous Predictors of Acute Coronary Syndrome Evaluation multinational registry (\(n=2,475, 32.2\%\) women), investigators noted that out of 34 chest pain characteristics, 29 were similar in men and women.\textsuperscript{39} Differences were observed only in chest pain radiation, intensity, and duration. Women more commonly reported radiation to the back and pain lasting for more than 30 minutes. Minority women reported more acute symptoms, albeit the symptoms differed by race (28% Hispanics, 38% Blacks, and 42% Whites reported no chest pain or discomfort). Eastwood et al found that Blacks experienced more stomach-related symptoms rather than chest-related symptoms, which were observed in Caucasians.\textsuperscript{40}

Other studies have also shown that men and women experience a majority of similar symptoms.\textsuperscript{41} Kreatsoulas et al showed that both sexes experienced chest pain equally, although women twice as often used the terms “discomfort”, “crushing”, “pressing”, and “bad ache” compared to men.\textsuperscript{42} Men and women equally reported pain in the arms, back, and shoulders, and there were no sex differences in non-chest pain symptoms such as shortness of breath, fatigue, sweating, and weakness, but women more often experienced a dry mouth than men. In a study of 736 (37% women) ACS patients presenting to the emergency department, shoulder and arm pain were predictive of ACS in both men and women. However, the predictive value of shoulder (OR 2.53; 95% CI =1.29–4.96) and arm pain (OR 2.15; 95% CI =1.10–4.20) in women was nearly twice that of men (OR 1.11; 95% CI =0.67–1.85 and OR 1.21; 95% CI =0.74–1.99).\textsuperscript{43}

In an analysis of more than 1.1 million AMI patients from the National Registry of Myocardial Infarction between 1994 and 2006, Canto et al showed that although, overall, young women were less likely to present with chest pain than men,\textsuperscript{44} young men and older patients also presented without chest pain. Further, compared with younger women, older women were more likely to present without chest pain. Even though women have had low symptom severity, the number of symptoms was high compared with men. Notwithstanding, women presenting without chest pain had greater mortality (Figure 3), which may be a function of delayed presentation, underdiagnosis, and undertreatment. The authors cautioned that labeling women with atypical chest pain can lead to poorer outcomes and that men and women had several common symptoms in ACS presentations. Similarly, in the GENESIS-PRAXY study, both men and women without chest pain had poorer access to care and worse outcomes.\textsuperscript{45}

While women have delays in presentation and higher clinical risk scores, men have more classic electrocardiography findings, allowing faster access to care.\textsuperscript{24} Female gender is strongly correlated with delayed hospital arrival and symptom to balloon time in STEMI due to low awareness, sociocultural and financial reasons.\textsuperscript{8,22,46,47} In a qualitative

![Figure 3](https://www.dovepress.com/)

Figure 3 Sex differences in prevalence of non-chest pain AMI presentation in young adults, and associated risks in young women compared with men presenting with chest pain.

Note: Data taken from Canto et al.\textsuperscript{44}

Abbreviations: AMI, acute myocardial infarction; CP, chest pain; HR, hazard ratio.
study of women between 30 and 55 years, authors noted that women were not accurately aware of their cardiovascular risks, reported poor preventative behaviors, and delayed seeking care for their symptoms.48 Despite significant risk factors, only one-half of men and women correctly perceived their risk of heart disease.49 Nevertheless, temporal analyses show that awareness has significantly increased among women; women also make greater use of ambulance services for medical assessment of chest pain.48,50 In the GENESIS-PRAXY study, young women were more likely to seek care than men (49% vs 42%, p=0.04), and among patients seeking care, women more often called for an ambulance (52% vs 39%).38

Pathophysiology

Majority of AMI occur in the context of plaque rupture; however, in a third of cases, thrombus occurs with an intact fibrous cap.51 Virmani et al were the first to describe plaque erosions in the context of AMI,52 observing that premenopausal women had more plaque erosion compared with plaque rupture noted in postmenopausal women. On the other hand, coronary thrombosis in the setting of calcific nodules is more common in elderly women. Plaque erosion, associated with a thick-cap fibroatheroma, smooth muscle cells, greater proteoglycans, few macrophages, and inflammatory cells, is the cause of 25%–30% of STEMI cases, and younger smokers are more often affected.51 Different biomarkers may be implicated in plaque erosion and rupture, serving as useful targets for disease modulation.53 Recent studies have examined whether use of intravascular imaging with optical coherence tomography is useful in AMI patients to detect plaque erosion, which may allow a different treatment strategy avoiding stenting.54,55

Angiographic characteristics and diagnostic dilemmas

Women tend to have less adverse anatomical characteristics than men with lower plaque burden and less calcification, particularly among younger women.20,56,57 In the PROSPECT trial, there were no differences in culprit lesion number, location, or complexity by sex. Women tended to have more plaque erosion whereas men had plaque rupture.58 In non-culprit lesions, women <65 years had lower prevalence of plaque rupture (1.2% vs 3.8%, p=0.01) and lower plaque volumes (46.8% vs 47.7%, p=0.04) than men.17 In both men and women in this study, non-culprit lesions were not significantly associated with long-term major adverse cardiovascular events.59

However, invasive angiography may be inaccurate, and intravascular imaging is often required to confirm the presence and extent of plaque. From the WISE trial, 80% of patients with normal coronaries on angiography were observed to have plaque in the coronaries on intravascular ultrasound.60 In a study by Reynolds et al (n=50 women), women with <50% angiographic stenosis often had evidence of plaque disruption on intravascular ultrasound (39% cases) and abnormal findings on cardiac magnetic resonance imaging (MRI; 59% cases).61

In a VIRGO sub-study, patients were grouped according to the type of MI using the third universal definition;62 while most patients had plaque-related MI (82.5% women, 94.9% men), other types included obstructive disease with (1.4% women; 0.9% men) and without (2.4% women; 1.1% men) supply demand mismatch, non-obstructive disease with (4.3% women; 0.8% men) and without supply demand mismatch (7.0% women; 1.9% men), other mechanisms for MI (1.5% women, 0.2% men), and unexplained MI (0.8% women, 0.2% men). The authors concluded that in 1 in 8 women has an undetermined cause of MI necessitating better understanding of disease mechanisms for improved prognosis.

Non-obstructive disease

Women have a high prevalence of non-obstructive disease on angiography.63–65 Chest pain and AMI in the absence of atherosclerotic or obstructive coronary disease may be due to several reasons including coronary vasospasm, microvascular ischemia, spontaneous coronary artery dissection (SCAD), and stress cardiomyopathy. Myocardial infarction with normal coronary arteries (MINOCA) tends to affect young women and includes both endothelial dysfunction and vasospasm in the epicardial vessels and endothelial dysfunction in the microvasculature.65 Various descriptors have been used for this scenario including, syndrome X, vasotonic angina, sensitive heart, angina with normal coronary arteries (MINOCA), and the overlapping term INOCA (ischemia and no-obstructive coronary artery disease).65,66

Table 3 summarizes some clinical studies examining prevalence, sex differences, and outcomes in ACS patients with non-obstructive disease.67–73 Although prevalence varies from 6% to 30% in women with ACS and outcomes are generally better than with obstructive disease, it is not a benign condition, and therefore, deserves careful evaluation. In the WISE study, the incidence of non-obstructive disease with core laboratory-assessed angiographic stenosis between 20% and 50% was quite common, occurring in 25% of women;
## Table 3 Clinical studies of ACS patients with non-obstructive disease

<table>
<thead>
<tr>
<th>Author</th>
<th>Study period</th>
<th>Data source</th>
<th>Sample size</th>
<th>Key outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>De Ferrari et al[^2]</td>
<td>2014</td>
<td>Patient-level meta-analysis from eight RCTs: GUSTO IIb, PURSUIT, PARAGON A, PARAGON B, SYNERGY, PRISM, PRISM-PLUS, and EARLY ACS</td>
<td>37,101 patients</td>
<td>- Women with non-obstructive disease were younger with lower prevalence of DM, prior MI or PCI</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Patients with non-obstructive disease had lower 30-day and 1-year mortality compared with patients with obstructive disease</td>
</tr>
<tr>
<td>Pasupathy et al[^4]</td>
<td>2016</td>
<td>Systematic review</td>
<td>28 studies for quantitative assessment; 46 studies for qualitative assessment</td>
<td>- Prevalence of MINOCA was 6%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Compared with MI-CAD, MINOCA patients were likely to be younger women but had similar risk factors</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- One-year all cause mortality was lower in MINOCA vs MI-CAD (4.7% vs 6.7%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- MRI in MINOCA patients showed infarct in 24%, myocarditis in 33%, and no abnormalities in 26%. Thrombophilia was noted in 14% and coronary spasm was inducible in 27%</td>
</tr>
<tr>
<td>Pizzi et al[^9]</td>
<td>Data until June 30, 2015</td>
<td>Systematic review and meta-analysis</td>
<td>33 studies, 120,548 patients</td>
<td>- Patients with non-obstructive disease have fewer risk factors than those with obstructive disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- They were more likely to be younger, female, with lower prevalence of diabetes, hypertension, and dyslipidemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- They have lower risk of future events, but not a benign prognosis. Yearly rates of death (2.4%) and MI (1.6%) were lower in non-obstructive disease than in obstructive disease (death 10.1%, MI 6.0%)</td>
</tr>
<tr>
<td>Johnston et al[^5]</td>
<td>2005–2010</td>
<td>SCAAR, Swedish Coronary Angiography and Angioplasty Registry</td>
<td>95,849 patients</td>
<td>- Non-obstructive disease has a prevalence of 7% in STEMI (6% in men, 10% in women) and 17% in NSTEMI (11% in men, 28% in women)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- It is more common in women than in men</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Non-obstructive disease was associated with higher risk of events in STEMI than in NSTEMI, during a median follow-up of 2.6 years</td>
</tr>
<tr>
<td>Hansen et al[^11]</td>
<td>2005–2007</td>
<td>Danish registry data</td>
<td>20,800 AMI patients, 834 women and 761 men without significant stenoses on angiography who were discharged and alive after 60 days</td>
<td>- More women than men have non-obstructive disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- There were no sex differences in discharge medications among patients with non-obstructive disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Women and men have similar outcomes with non-obstructive disease</td>
</tr>
<tr>
<td>Chokshi et al[^2]</td>
<td>May to September 2006</td>
<td>Two-center registry</td>
<td>518 patients</td>
<td>- Women are more likely than men to have non-obstructive disease overall (32% vs 15%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Women with MI are more likely than men to have non-obstructive disease (32% vs 11%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Black patients were more likely to have non-obstructive disease (36%) than other subgroups – White (18%), Hispanic (21%), Asian (9%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Among women, Black patients had greater non-obstructive disease (59%) than other ethnic groups – White (29%), Hispanic (28%), Asian (6%)</td>
</tr>
<tr>
<td>Gehrie et al[^13]</td>
<td>2001–2005</td>
<td>CRUSADE registry</td>
<td>4,903 patients with non-obstructive disease, 2,282 women</td>
<td>- Non-obstructive disease was noted in 9.5%; 60% were women</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- More than 50% NSTEMI patients with non-obstructive disease had troponin values &gt;5 upper limit of normal (58.9% women vs 58.6% men)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- 89% women vs 87% men had positive TNI values despite non-obstructive disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Females with non-obstructive disease were older than males with greater risk factors</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Males and females with non-obstructive disease had similar rates of in-hospital death, reinfarction, and other clinical outcomes</td>
</tr>
</tbody>
</table>

**Abbreviations:** ACS, acute coronary syndrome; AMI, acute myocardial infarction; CAD, coronary artery disease; DM, diabetes mellitus; MI, myocardial infarction; MINOCA, myocardial infarction with normal coronary arteries; MRI, magnetic resonance imaging; NSTEMI, non-ST-elevation MI; PCI, percutaneous coronary intervention; RCT, randomized controlled trial; STEMI, ST-segment elevation MI; TNI, troponin I.
no disease occurred in 37% and obstructive disease was present in 38%.61 Ten-year cardiovascular death or MI occurred in 6.7%, 12.8%, and 25.9% of patients with no disease, non-obstructive disease, and obstructive CAD. Jespersen et al noted that two-thirds of women undergoing coronary angiography for stable angina, compared with men, had non-obstructive CAD.64 Both diffuse non-obstructive disease (HR 1.85, 95% CI =1.51–2.28) and angiographically normal coronaries (HR 1.52, 95% CI =1.27–1.83) were associated with greater risk of major adverse cardiac events (MACE) compared to an asymptomatic reference population.

**Microvascular dysfunction and coronary vasospasm**

Nearly two-thirds of women with non-obstructive disease may have evidence of microvascular dysfunction.74 The cause for coronary microvascular dysfunction (CMD) may be epicardial abnormal vasomotion or endothelial microvascular dysfunction, atherosclerotic emboli or inflammation.66,75 CMD has been noted both in the presence and in the absence of traditional cardiovascular risk factors.75 Microvascular ischemia can be objectively tested using echo Doppler, positron emission tomography, cardiac MRI, or invasive assessment of coronary flow reserve (CFR).66,75 In the recent white paper on INOCA, Bairey Merz et al summarize clinical studies testing for microvascular dysfunction in stable angina.66

Treatment for suspected microvascular ischemia includes calcium channel blockers and nitrates.66 Statins, angiotensin-converting enzyme inhibitors, and amitriptyline may be beneficial via a vasodilatory action. While smaller studies have shown that ranolazine increases CFR, it has not been shown to decrease clinical events in a randomized controlled trial. In the WISE study, low CFR was associated with greater circulating progenitor cells suggesting that chronic ischemia stimulates release and circulation of progenitor cells.76 This finding requires further examination as a potential biomarker for targeted treatment.

Coronary vasospasm, variant or Prinzmetal’s angina, is caused by vagal withdrawal or increase in sympathetic drive, albeit other mechanisms may play a role such as decrease in nitric oxide, increase in phospholipase C, or magnesium deficiency.65,77 It is common in young patients and smokers and frequently associated with ST-segment elevation or ventricular arrhythmias, but may also be caused by ingestion of recreational drugs (cocaine, cannabis, and amphetamines) or chemotherapy, antibiotics, and anti-migraine medications.77 Studies are conflicting on prevalence by sex — some studies have shown it is more common in women.78,79 In one study, outcomes were worst in young females presenting with coronary vasospasm.80 Treatment includes calcium channel blockers and nitrates. Statins are anti-inflammatory and may be beneficial through inhibition of rho-associated kinase.77

**Spontaneous coronary artery dissection**

SCAD is defined as a tear or separation in the layers of the coronary artery wall between the intima and the media, which is spontaneous and may be associated with intramural hemorrhage.81 Majority of patients tend to be young women in the peripartum period, although an association has also been observed with fibromuscular dysplasia, with a SCAD prevalence of 25%–86% in this subset.82 Presentation is commonly with STEMI and may be associated with ventricular arrhythmias or sudden cardiac death.83,84 Although different angiographic types have been recognized, currently, the term SCAD is used to refer only to non-atherosclerotic variants of the disease.81 Diagnosis may be facilitated by the use of intravascular imaging.85 Treatment tends to be conservative rather than coronary stenting for risk of extending the dissection flap, but is dependent on the individual clinical setting. However, recurrence has been noted in up to 13%–17% of patients;82,84 hence, follow-up is crucial. SCAD is also associated with a high prevalence of anxiety and depression, particularly among young women and those with peripartum SCAD.82,85 Thus, dedicated follow-up and rehabilitation can assist in early recognition for channeling appropriate specialist care.86,87 After the initial diagnosis of SCAD, computed tomography angiography may be useful in patients with recurrent chest pain or to monitor for lesion healing.88 Recently, the Mayo clinic Virtual SCAD registry compared 54 pregnancy-related SCAD (P-SCAD, during pregnancy or within 12 weeks postpartum) patients with 269 non-pregnancy-related patients and noted that P-SCAD patients had more acute presentations and high-risk features such as STEMI, left main and/or multivessel SCAD, or reduced left ventricular function.89 Over a median follow-up of 2.3 years, there was no statistically significant difference in recurrence rates (10% vs 23%, p=0.18).

**Stress cardiomyopathy**

Takotsubo (stress) cardiomyopathy is a left ventricular apical ballooning syndrome, triggered by emotional or physical stress and noted more often in older postmenopausal women, commonly presenting as ACS or STEMI in the absence of obstructive coronary disease.89 In a large international registry, the mean age of women presenting with Takotsubo syndrome was 66±8±13 years, but men compared with women experienced worse short- and long-term mortality.89 Some reports indicate that this condition may also be noted.
in younger patients suggesting that physicians should remain vigilant when other causes for MI have been excluded.\(^\text{90}\)

**Pregnancy-related complications and premature atherosclerosis**

Pregnancy-related complications such as gestational diabetes, gestational hypertension, preeclampsia, low birthweight, and preterm labor are associated with endothelial dysfunction, metabolic derangements, and premature atherosclerosis contributing to future risk of cardiovascular events.\(^\text{31}\) Similarly, infertility and high parity are associated with greater risks, although precise mechanisms are unclear.\(^\text{91}\) It is crucial to manage cardiovascular risk early in these women through specialist cardiology referral organized by the obstetrician or general practitioner.

**Clinical outcomes**

Based on pooled data for the period 1995–2010 from the Framingham Heart Study, Multi-Ethnic Study of Atherosclerosis, Atherosclerosis Risk In Communities, and Coronary Artery Risk Development in Young Adults, the 2016 Heart and Stroke Statistics update reported that for patients between 45 and 64 years of age, within 1 year of first MI, 3% White men, 5% White women, 9% Black men, and 10% Black women will die.\(^\text{22}\) Tables 4 and 5 summarize key findings from selected clinical studies. With respect to temporal trends, Gupta et al showed from the AHRQ HCUP NIS that among patients between 2001 and 2010, young women <55 years of age had longer in-hospital stay and greater in-hospital mortality than men.\(^\text{12}\) Nevertheless, over time, women showed a 30.6% decrease in in-hospital mortality (3.3% to 2.3%, p-trend <0.001), whereas rates were stable for men (8.5% decrease, 2.0%–1.8%, p-trend =0.60).

Several data have shown that young women have worse long-term outcomes than men after ACS presentation, correlated with worse baseline risk factors.\(^\text{17–19,92}\) In the PROMETHEUS observational study, women <55 years of age undergoing ACS percutaneous coronary intervention (PCI) had significantly greater rates of 1-year MACE (21.1% vs 16.2%, p<0.001) and clinically significant bleeding (3.6% vs 2.2%, p=0.01) than men, but after adjustment for baseline differences, outcomes were similar (HR for MACE 1.13, 95% CI =0.94–1.36 in women compared to men; HR for bleeding 1.31, 95% CI =0.85–2.04) suggesting that unadjusted differences were not due to biological variances.\(^\text{99}\) In the HORIZONS AMI randomized trial, which included 3,602 STEMI patients (23.4% women, 40% elderly women ≥70 years), female sex was found to be an independent predictor of bleeding events (HR 1.81, 95% CI =1.41–2.33, p<0.001) but not MACE (HR 1.09, 95% CI =0.91–1.32, p=0.35), which may be linked with greater use of femoral access (~94.0%) and glycoprotein 2b3a inhibitor use in this study.\(^\text{18}\) Similarly, in the TRANSLATE-ACS study, unadjusted but not adjusted 1-year MACE was higher in women undergoing ACS PCI (15.7% vs 13.6%, p=0.02; HR 0.98, 95% CI =0.83–1.15). Conversely, despite adjustment, bleeding remained significantly greater for women (GUSTO bleeding 9.1% vs 5.7%; HR 1.32, 95% CI =1.27–1.56).\(^\text{17}\)

However, yet other studies have found persistently greater risk attributed to women even after adjustment for potential confounders. Data from the NRMI registry on 1.1 million patients between 1994 and 2006 showed that women with AMI presenting without chest pain had higher in-hospital mortality than men (14.6% vs 10.3%, p<0.001), albeit mortality risk decreased with increasing age.\(^\text{44}\) In a recent Canadian observational study for 23,473 ACS patients from 2008 to 2011, women had higher propensity-adjusted risk of 1-year rate of death or recurrent ACS (13.0% in women and 10.0% in men; HR 1.24, 95% CI =1.16–1.33).\(^\text{99}\) In contrast, revascularization outcomes were similar in women compared to men (17.8% vs 16.9%; HR 1.06, 95% CI =0.99–1.14). In an observational study of young ACS patients (<55 years of age) from Israel, female sex was observed to be an independent predictor of in-hospital mortality (HR 4.1, 95% CI =1.15–14.0), 30-day major adverse cardiac and cerebrovascular events (HR 2.1, 95% CI =1.31–3.36), and 5-year mortality (HR 1.96, 95% CI =1.3–2.8).\(^\text{23}\) Interestingly, investigators of the GENESIS PRAXY study noted that female gender but not female sex was associated with greater risks and 1-year adverse outcomes.\(^\text{94}\)

Rodriguez et al studied racial and sex differences from 194,071 patients taken from the NIS database for the period 2009–2010.\(^\text{95}\) Among patients <65 years of age, Hispanic and Black women had longer length of stay than younger White men. After multivariable adjustment, young Hispanic women had greater risk of adverse events compared with White men (OR 1.5, 95% CI =1.2–1.9). Younger Hispanic women had higher in-hospital mortality (3.7%) compared with Black (3.1%) and White young women (2.5%). The recent PLATINUM DIVERSITY multicenter US study was specifically designed to analyze outcomes in women and minorities undergoing PCI who are underrepresented in PCI trials compared with White men.\(^\text{96}\) The authors noted that women and minorities had higher incidence of 1-year death or MI compared with White men, albeit MACE outcomes were similar.
Outcomes were similar in older women vs older men

More women than men with ACS were Black (19.7% vs 10.5%)

Five nationwide registries

Compared with older women, younger women had higher rates of non-reperfusion (68.4% vs 76.7%, p<0.001) with PCI (OR 0.74, 95% CI =0.73–0.75), CABG (6.1% vs 8.0%, OR 0.61, 95% CI =0.60–0.62), or thrombolysis (4.2% vs 4.5%, OR 0.80, 95% CI =0.78–0.82) than men

In-hospital mortality was greater in young women than in men (4.5% vs 3.0%, OR 1.11, 95% CI =1.07–1.15)

There was a decrease in STEMI rates over time with increase in NSTEMIs (p<0.001)

In-hospital mortality increased with age. Female sex was an independent predictor of in-hospital mortality (OR 1.44, 95% CI =1.07–1.93, p=0.009)

Rates of non-reperfusion in patients <55 years was 19% for women in 2014 compared with 5% in men in the same age group. Primary PCI was used in 66% women vs 83% men in this age group

For patients between 55 and 64 years, non-reperfusion rate was 12% in women compared with 8% in men

In-hospital mortality was low in men and women <55 years. In patients between 55 and 64 years, in-hospital mortality occurred in 3.4% women vs 1.3% men. Rates of major bleeding were higher in women than in men

In-hospital mortality decreased over time in both men and women, but less so in women

Table 4 Selected clinical studies of young women with AMI/ACS presentation

<table>
<thead>
<tr>
<th>Author</th>
<th>Study period</th>
<th>Data source</th>
<th>Sample size</th>
<th>Key outcomes</th>
</tr>
</thead>
</table>
| Khera et al | 2004–2011 | United States Nationwide inpatient sample | 632,930 adults with STEMI <60 years of age, 74.7% White | • Young women were less likely to present with STEMI (38.4% vs 49.4% OR 0.74, 95% CI =0.73–0.75)  
• Women underwent less angiography than men at each time point  
• Women underwent less reperfusion (68.4% vs 76.7%, p<0.001) with PCI (OR 0.74, 95% CI =0.73–0.75), CABG (6.1% vs 8.0%, OR 0.61, 95% CI =0.60–0.62), or thrombolysis (4.2% vs 4.5%, OR 0.80, 95% CI =0.78–0.82) than men  
• In-hospital mortality was greater in young women than in men (4.5% vs 3.0%, OR 1.11, 95% CI =1.07–1.15)  
• There was a decrease in STEMI rates over time with increase in NSTEMIs (p<0.001) |
| Gupta et al | 2001–2010 | United States Nationwide inpatient sample | 230,684 young AMI hospitalizations in adults 30–54 years of age (25.9% women) | • Hospitalization rates for young adults did not decline over time  
• There was no difference in hospitalization rates for AMI by sex in patients <55 years of age  
• Women had longer length of stay and greater in-hospital mortality  
• In-hospital mortality declined over time by 30.6% in women (2.3% to 2.3%, p-trend <0.001), but remained stable in men (2.0% to 1.8%, p-trend =0.60)  
• More women than men with ACS were Black (19.7% vs 10.5%)  
• Black women had higher rates of hospitalization and comorbidities than White women  
• In-hospital mortality was higher in Blacks than in Whites, for both men and women |
| Canto et al | 1994–2006 | NRMI | 1.1 million AMI patients (42.1% women); 66,540 adults <45 years; 132,777 adults 45–54 years | • More women than men presented without chest pain (42.0% vs 30.7%, p<0.001)  
• There was a larger sex difference in non-chest pain presentations in younger than older adults (15.3% women vs 10.2% men <45 years; 14.5% women vs 10.6% men 45–54 years)  
• Compared with young women, older women had more non-chest pain presentations (15.3% in women <45 years, 21.8% in women ≥75 years)  
• Women vs men had greater in-hospital mortality (14.6% vs 10.3%)  
• Younger women presenting without chest pain had greater risk of in-hospital mortality than young men; this risk decreased with age — In women <45 years vs men: adjusted OR 1.18 (1.00–1.39)  
— In women 45–54 years vs men: adjusted OR 1.13 (1.02–1.26)  
• Compared with older women, younger women had higher rates of 1-year MACe (27.8% vs 19.9%; p=0.003) due to greater TLF  
• Compared with older women, younger women had higher 5-year rates of repeat procedures (10.7% vs 6.8%, p=0.04)  
• Overall, women had worse outcomes than men  
• Outcomes were similar in older women vs older men |
| Epps et al | 1997–2006 | NHLBI Dynamic registry | 10,963 PCI patients (3,797 women, 394 <50 years) | • Compared with older women, younger women had higher rates of 1-year MACE (27.8% vs 19.9%; p=0.003) due to greater TLF  
• Compared with older women, younger women had higher 5-year rates of repeat procedures (10.7% vs 6.8%, p=0.04)  
• Overall, women had worse outcomes than men |
| De Luca et al | 2001–2014 | Five nationwide pooled Italian registries | 13,235 patients, 27.9% women; 376 women <55 years; 558 women 55–64 years | • In-hospital mortality increased with age. Female sex was an independent predictor of in-hospital mortality (OR 1.44, 95% CI =1.07–1.93, p=0.009)  
• Rates of non-reperfusion in patients <55 years was 19% for women in 2014 compared with 5% in men in the same age group. Primary PCI was used in 66% women vs 83% men in this age group  
• For patients between 55 and 64 years, non-reperfusion rate was 12% in women compared with 8% in men  
• In-hospital mortality was low in men and women <55 years. In patients between 55 and 64 years, in-hospital mortality occurred in 3.4% women vs 1.3% men. Rates of major bleeding were higher in women than in men  
• In-hospital mortality decreased over time in both men and women, but less so in women |

(Continued)
Women with ACS have also been shown to have greater rehospitalization rates than men. In the GENESIS-PRAXY study, women had greater all-cause (13% vs 9%, \( p = 0.006 \)) but not cardiac rehospitalizations.\(^9\) Dreyer et al analyzed young patients aged 18–64 years with a principal diagnosis of AMI from the HCUP-State Inpatient Database for California (2007–2009) and found that women were more likely than men to have increased 30-day readmissions (15.5% vs 9.7%, \( p < 0.0001, \) adjusted hazard ratio, 1.22; 95% CI = 1.15–1.30).\(^9\) However, women more commonly than men had readmissions from non-cardiac reasons (44.4% vs 40.6%, \( p = 0.01 \)). In the TRIUMPH study, women had a 26% increase in 1-year rehospitalization.
Table 5 Clinical studies of AMI patients examining outcomes by race and sex

<table>
<thead>
<tr>
<th>Author</th>
<th>Study period</th>
<th>Data source</th>
<th>Sample size</th>
<th>Key outcomes</th>
</tr>
</thead>
</table>
| Gupta et al  | 2001–2010    | United States NIS            | 230,684 young AMI hospitalizations in adults 30–54 years of age (25.9% women) | • More women than men with ACS were Black (19.7% vs 10.5%)  
• Black women had higher rates of hospitalization and comorbidities than White women  
• In-hospital mortality was higher in Blacks than in Whites, both for men and women  
• Greater declines were noted in age-adjusted AMI hospitalization rates in White men and women (30.8% and 31.4%, respectively) compared with Black men and women (13.6% and 12.6%) over the study period  
• Women underwent less catheterization than men  
• White women had higher catheterization and PCI rates than women of other races  
• Hispanic women had greater in-hospital mortality than White men (OR 1.5, 95% CI =1.2–1.9) |
| Wang et al   | 2001–2007    | NIS from the HCUP            | 2,179,509 AMI hospitalizations (not restricted to young AMI) |                                                                                                                                             |
| Rodriguez et al | 2009–2010 | NIS                           | 194,071 AMI patients; 43% patients <65 years of age; 17,455 White women, 4,694 Black women, 2,116 Hispanic women |                                                                                                                                             |
| Edmund et al | 2008–2011    | ACTION Registry Get with the guidelines database | 175,370 AMI patients (STEMI: 18,771 White women; 2,283 Black women; NSTEMI: 35,241 White women; 5,702 Black women) | • Catheterization rates were similar by race for STEMI; Blacks underwent less catheterization than Whites for NSTEMI  
• Revascularization rates were lower for Blacks than Whites for STEMI and NSTEMI  
• Black women were less likely to undergo catheterization and PCI than White women in low and intermediate ACTION risk groups but not in high ACTION risk groups |
| Batchelor et al | 2011–2014 | PLATINUM Diversity study pooled with the Premier Element PAS cohort | 4,188 patients (1,863 women, 55% ACS and 1,059 minorities, 53% ACS) (not restricted to young AMI) | • Women and minorities were older with greater prevalence of diabetes at baseline compared with White men  
• Women and minorities had higher adjusted risk of 1-year death or MI compared with White men  
• Women and minorities were less likely to remain on dual antiplatelet therapy at 1 year compared with White men |

Abbreviations: ACS, acute coronary syndrome; ACTION, Acute Coronary Treatment and Intervention Outcomes Network; AMI, acute myocardial infarction; HCUP, Healthcare Cost and Utilization Project; MI, myocardial infarction; NIS, National Inpatient Sample; NSTEMI, non-STEMI; PAS, post approval study; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation MI.

AMI rehospitalizations even after adjustment for clinical risks. However, after adjustment for health status and psychosocial factors, these differences were attenuated and no increased risk or interaction by sex was noted.

Treatment bias
A treatment bias has long been described for women presenting with AMI. Despite significantly higher risk of adverse events, women are less likely to be referred for cardiac catheterization or PCI, due to underdiagnosis and perceived risk of complications. In the Canadian ACS study by Udell et al, 66.1% men and 51.8% women received cardiac catheterization in the same admission. In the Israeli ACS registry, even after adjustment for GRACE score, diabetes, and year of enrolment, young women <55 years of age were less likely to undergo in-hospital coronary angiography (OR 0.6, p=0.007). In data from the Korean nationwide registry (Korea Working Group of Myocardial Infarction) between November 2005 and July 2011, women ≤50 years of age were more likely to be treated with conservative management (30.4% vs 11.2%, p<0.001) and less likely to receive optimal medical therapy and less PCI (69.5% vs 89%, p<0.001) with lower rates of PCI success (85.8% vs 92.2%, p<0.001). In the GENESIS-PRAXY study, 13% women vs 3% men (p=0.01) reported no intervention done. Rodriguez et al noted that among patients <65 years, women were less likely to undergo angiography and PCI than men among all races. Nevertheless, young White women had higher rates of angiography compared with women of other races.

Women are also less likely to receive evidence-based therapies than men. In the WISE study, during 1-year follow-up, women with non-obstructive disease were less likely to receive statins (12% in women with no disease vs 33% in non-obstructive disease vs 53% in obstructive disease) and other medications compared with patients with obstructive disease. In the GENESIS-PRAXY study, use of cardiovascular risk reduction therapies was ±40% in both men and women, and <50% patients perceived that their provider attributed a cardiac cause for the presentation. In the PROMETHEUS study, prasugrel was less often used...
in young women than men <55 years of age (28.1% vs 31.8%, p=0.01), ostensibly due to greater perceived risk of bleeding; however, bivalirudin was also used less often in women (28.0% vs 31.7%, p=0.016). 19

Although this bias has decreased over the last couple of decades, there still remains a gap in the treatment of men and women. The exact reasons for this gap need to be explored in future studies but may include sociocultural reasons and delayed referrals in women. 8

Rehabilitation and health quality post-ACS
Prior research has shown that women are less likely to be referred for cardiac rehabilitation than men, despite guideline recommendations. 9 Some factors limiting attendance at rehabilitation might be depression, arthritis, distance from the hospital, and poor social support, which can be overcome by home- and community-based approaches. 102 Cardiac rehabilitation dropout rates are highest in young women, with high depression and anxiety scores, even though rehabilitation and physical activity have been shown to alleviate depression. 103 In a small randomized trial, dedicated rehabilitation with motivational interviewing was superior to traditional cardiac rehabilitation in women for reducing depressive symptoms. 104 Contemporary approaches using digital health technology may be successfully used to encourage young patients to complete cardiac rehabilitation. 105

In the GENESIS-PRAXY study, both baseline and 1-year health behavior profiles of young patients were worse than the general population, albeit small improvements noted at 1-year post-ACS. 106 At baseline, men had lower intake of fruit and vegetables but greater alcohol and recreational drug consumption compared with women. At 1-year post-ACS, only 5% more men and 1% more women consumed ≥5 daily servings of fruit and vegetables. Women with ACS continued to smoke twice as much as the general population at 1-year post-ACS.

In the VIRGO study, Minges et al found that young men exercised more often than women at baseline (42% vs 34%), 1 month (45% vs 34%), and 12 months (48% vs 36%) after ACS presentation (p<0.001 for all). 107 Even after adjustment for baseline confounders, young women were less likely to be active from baseline to 12 months (HR 1.37, 95% CI =1.21–1.55). Women were also less likely to return to work than men (85% vs 89%, p=0.02), especially in occupations involving physical labor. 108 Being married, engaged in a professional or clerical job, better physical health, and no previous CAD or hypertension were associated with higher likelihood of returning to work. Low perceived social support had a significant impact on health outcomes in young men and women after AMI. 109

While fewer young women than men discuss risks and risk factor modification with their physicians, younger patients are also rarely given sexual counseling after AMI and are commonly given restrictions not based on guidelines. 59, 110

Conclusion
The incidence of AMI in young women is increasing in conjunction with increasing lifestyle risk factors and greater prevalence of diabetes, obesity, and metabolic syndrome. Risk factors are evolving and non-traditional risk factors such as depression, anxiety, and stress warrant careful consideration in clinical assessment. Non-atherosclerotic mechanisms of ACS should be evaluated in patients without obstructive disease, since non-diagnosis can result in high morbidity and healthcare costs. Along with improvements in symptom awareness of young women for early presentation, focus on secondary prevention with guideline-directed therapies is necessary to improve outcomes. Dedicated post-ACS care and rehabilitation may be tailored to patient needs to optimize long-term health-related quality of life.

Disclosure
The authors report no conflicts of interest in this work. Dr Mehran has received institutional grant support from AstraZeneca, The Medicines Co., Bristol-Myers Squibb/Sanofi, and Eli Lilly and Company/Daiichi Sankyo. Dr Mehran is a consultant for AstraZeneca, Bayer, CSL Behring, Janssen Pharmaceuticals, Merck & Co, The Medicines Co., and Watermark Consulting. She serves on the advisory board of Abbott Laboratories, AstraZeneca, Boston Scientific, Coviden, Janssen Pharmaceuticals, Merck & Co., The Medicines Co., and Sanofi-Aventis and has equity in Claret Medical and Elixir Medical Corp. Dr Chandrasekhar and Ms Gill have no financial disclosures.

References


